Saturday, January 12, 2008

Pediatric MS

Pediatric MS
WHOI - Peoria,IL,USA
Primary-progressive MS accounts for about 10 percent of all cases. It is characterized by a slow, but steady progression of symptoms. ...
See all stories on this topic

New MS drug
WCBD-TV - Mt. Pleasant,SC,USA
... A Virginia research center is one of 45 sites across the country studying a new potential drug to treat Secondary Progressive Multiple Sclerosis. ...

Combination therapy including antibiotics may be beneficial for ... - Sydney,Australia
A preliminary study suggests that combining a medication currently used to treat multiple sclerosis with an antibiotic may slow the progress of the disease, ...
See all stories on this topic

Bayhill Therapeutics, Inc. Files Registration Statement for ...
Business Wire (press release) - San Francisco,CA,USA
Bayhill’s lead product candidate, BHT-3009, for the treatment of multiple sclerosis has completed a Phase II proof-of-concept clinical trial. ...
See all stories on this topic

$500000 Prize for Faster Airport Security Checks
Slashdot - USA
My mum has multiple sclerosis and the Rebif medication she takes is temperature/pressure sensitive meaning it must be taken on board the plane along with ...
See all stories on this topic

Checking in on Biogen
Motley Fool - USA
Much of Biogen's forecast for this time frame depends on its and Elan's (NYSE: ELN) multiple sclerosis drug, Tysabri, reaching an optimistic 100000 patient ...
See all stories on this topic

Biogen Idec Gets a Near-Term Boost
Barron's - USA
With respect to Tysabri, management indicated that 12900 US patients and 7500 patients internationally were on Tysabri in late December 2007. ...
See all stories on this topic

ADRs in Focus: European Pharma
Houston Chronicle - United States
PLC, which markets the multiple sclerosis drug Tysabri, added 66 cents, or 2.8 percent, to $23.87. AstraZeneca PLC, the British company that makes ...
See all stories on this topic

Tysabri sales up, boosting Biogen
Trading Markets (press release) - Los Angeles,CA,USA
based company, which manufactures Tysabri in Research Triangle Park, also said 2007 earnings will surpass the company's earlier forecasts. ...
See all stories on this topic

CORRECTED-UPDATE 1-No new brain-infection cases with Biogen drug
Reuters - USA
(Corrects Oct. 11 story to show date of Tysabri's return to market was July 2006, not last July) (Updates with details, analyst comment) BOSTON, ...
See all stories on this topic

Biogen Idec and Elan Provide Update on Utilization, Safety and ...
InfoBolsa - Spain
Patient Exposure of TYSABRI(R) in Patients with Multiple Sclerosis 07/01/2008 07:00:00 Business Wire For more detailed information on the risks and ...
See all stories on this topic

Bayhill Files for IPO
Private Equity Hub - Boston,MA,USA
Bayhill Therapeutics Inc., a Palo Alto, Calif.-based drug company focused on autoimmune diseases like multiple sclerosis, has filed for an $86.25 million ...
See all stories on this topic

Montel Williams hosting MS poker fundraiser - USA
In 1999 Williams was diagnosed with MS. He has since made pledges to use his celebrity to find a cure. Multiple Sclerosis is a chronic, inflammatory, ...
See all stories on this topic

Wednesday, January 09, 2008 Montel WIlliams Hosts Celebrity Poker ...
Bluff - Atlanta,GA,USA
The Montel Williams MS Foundation is dedicated to furthering the scientific study of multiple sclerosis. Its goals are to provide financial assistance to ...
See all stories on this topic

Montel Williams to Host MS Charity Poker Tourney - Las Vegas,NV,USA
Since being diagnosed with multiple sclerosis in 1999, the Emmy Award winner has been passionately committed to raising money and awareness for the disease. ...
See all stories on this topic

Montel Williams' Mantra: Get Juiced!
Express from The Washington Post - Washington,DC,USA
WILLIAMS: Oh, darling, without a doubt. When I was diagnosed with multiple sclerosis, I set about a path to see if I could mitigate my symptoms as they got ...
See all stories on this topic

Bayer says MS drug a possible blockbuster
MarketWatch - USA
Alemtuzumab, which entered Bayer's pipeline through the acquisitions of Schering AG, is already approved for the treatment of leukemia as Campath. ...
See all stories on this topic

St. Clair stop-smoking program free
Belleville News Democrat - IL, USA
Combining a medication currently used to treat multiple sclerosis (MS) with an antibiotic may slow the disease's progress, according to a preliminary study ...
See all stories on this topic

Antares lands fourth Teva deal - London,UK
Among the products Teva currently has in its R&D pipeline is an increased dose version of its successful multiple sclerosis drug, Copaxone (glatiramer ...
See all stories on this topic

Memory Consolidation Improved By Daytime Sleep
A ninety minute daytime nap helps speed up the process of long term memory consolidation, a recent study conducted by Prof. Avi Karni and Dr. Maria Korman of the Center for Brain and Behavior Research at the University of Haifa found.
Declining Memory And Lack Of Imagination Linked In Older Adults
Most children are able to imagine their future selves as astronauts, politicians or even superheroes; however, many older adults find it difficult to recollect past events, let alone generate new ones.
Brain Development Controlled By BERT And ERNI Proteins
Scientists at University College London have discovered how two proteins ­called BERT and ERNI interact in embryos to control when different organ systems in the body start to form, deepening our understanding of the development of the brain and nervous system and expanding our knowledge of stem cell behavior
Alseres Pharmaceuticals Concludes Enrollment In The Cethrin(R) Phase I/IIa Clinical Trial In Acute Spinal Cord Injury
Alseres Pharmaceuticals, Inc., (Nasdaq: ALSE), announced that it has concluded enrollment in the Phase I/IIa clinical trial of Cethrin in acute spinal cord injury (SCI). A total of 48 subjects have been enrolled at 9 sites in the United States and Canada.
Walking Restored After Spinal Cord Injury
Spinal cord damage blocks the routes that the brain uses to send messages to the nerve cells that control walking. Until now, doctors believed that the only way for injured patients to walk again was to re-grow the long nerve highways that link the brain and base of the spinal cord.


Post a Comment

Links to this post:

Create a Link

<< Home